US 12,268,748 B2
Nucleic acid nanostructures crosslinked with oligolysine
William M. Shih, Cambridge, MA (US); Zhao Zhao, Cambridge, MA (US); and Frances M. Anastassacos, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/602,740
Filed by President and Fellows of Harvard College, Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Apr. 9, 2020, PCT No. PCT/US2020/027435
§ 371(c)(1), (2) Date Oct. 8, 2021,
PCT Pub. No. WO2020/210468, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/831,858, filed on Apr. 10, 2019.
Prior Publication US 2022/0160885 A1, May 26, 2022
Int. Cl. A61K 47/60 (2017.01); A61K 47/69 (2017.01); C12Q 1/68 (2018.01)
CPC A61K 47/60 (2017.08) [A61K 47/6929 (2017.08)] 20 Claims
 
1. A composition comprising a deoxyribonucleic acid (DNA) nanostructure covalently linked to oligolysine-polyethylene glycol (PEG) copolymer.